To identify a screening strategy for dry eye patients with a high likelihood of having Sjogren syndrome (SS) through the evaluation of the association of ocular surface tests with the extraocular signs used for the diagnosis of SS.
Multicenter cross-sectional study.
The Sjogren’s International Clinical Collaborative Alliance (SICCA) registry enrolled 3514 participants with SS or possible SS from 9 international academic sites. Ocular surface evaluation included Schirmer I testing, tear breakup time (TBUT), and staining of the cornea (0–6 points) and conjunctiva (0–6 points). Multivariate logistic regression analysis was performed to identify predictive factors for (1) histopathologic changes on labial salivary gland (LSG) biopsies (positive = focus score of ≥1 focus/4 mm 2 ) and (2) positive anti-SSA/B serology.
The adjusted odds of having a positive LSG biopsy were significantly higher among those with an abnormal Schirmer I test (adjusted OR = 1.26, 95% CI 1.05–1.51, P = .014) and positive conjunctival staining (for each additional unit of staining 1.46; 95% CI 1.39–1.53, P < .001) or corneal staining (for each additional unit of staining 1.14; 95% CI 1.08–1.21, P < .001). The odds of having a positive serology were significantly higher among those with an abnormal Schirmer I test (adjusted OR = 1.3; 95% CI 1.09–1.54, P = .004) and conjunctival staining (adjusted OR = 1.51; 95% CI 1.43–1.58, P < .001).
In addition to corneal staining, which was associated with a higher likelihood of having a positive LSG biopsy, conjunctival staining and abnormal Schirmer I testing are of critical importance to include when screening dry eye patients for possible SS, as they were associated with a higher likelihood of having a positive LSG biopsy and serology.
Sjögren syndrome (SS) is the second most common autoimmune disease, affecting nearly 4 million Americans, with an estimated prevalence of 0.5%–5%.
Although the disease is common, diagnosis is often delayed by an average time of 6.5 years from symptom onset, and the majority of SS patients are undiagnosed. Diagnostic delays are of great clinical significance, as studies have consistently identified SS as an independent risk factor for non-Hodgkin lymphoma. Early detection of SS is important because patients who are started on biological agent treatment within the first 5 years of disease onset may be more likely to respond to treatment than those with delayed initiation of therapy.
Clinically, SS is characterized by hypofunction of the salivary and lacrimal glands, which typically leads to dry mouth and dry eye, although it may affect any organ system in the body. Because SS affects many organ systems, collaboration among multiple medical specialties is required and often contributes to delays in diagnosis. Currently, there are 2 sets of criteria used for the diagnosis of SS: the American-European Consensus Group (AECG) criteria and the more recent set of classification criteria developed by the Sjögren’s International Collaborative Clinical Alliance (SICCA) group and provisionally endorsed by the American College of Rheumatology (ACR). The ACR criteria define SS as requiring 2 out of 3 of the following signs: (1) positive serology (anti-SSA/SSB positivity or positive rheumatoid factor [RF] and antinuclear antibodies [ANA] ≥1:320); (2) presence of focal lymphocytic sialadenitis (FLS) with a focus score (FS) ≥1/4 mm 2 on a labial salivary gland (LSG) biopsy (“positive LSG biopsy”); or (3) an ocular staining score (OSS) ≥3. Recently, a revised set of classification criteria (ACR/European League Against Rheumatism) has been proposed in an attempt to reconcile differences between the AECG and ACR/SICCA criteria (Shiboski CH, American College of Rheumatology 2015).
Because dry eye is one of the most common symptoms of SS, patients often first seek care from eye care providers, who can potentially play a key role in reducing time from symptom onset to diagnosis. Previous studies have shown that up to 10% of dry eye patients have SS. However, because of the high prevalence of dry eye disease, it is not practical or economically feasible for ophthalmologists to refer all dry eye patients for an SS evaluation. In addition, screening is challenging, as there is currently no universal standard regarding which dry eye patients should undergo a comprehensive evaluation for SS (that includes a rheumatologic evaluation with specific blood work, and an LSG biopsy).
Historically, assessment of dry eye symptoms alone has not been helpful in screening patients for SS, as multiple autoimmune diseases may present with dry eye symptoms without any known symptoms specific for SS-related dry eye. Similarly, severity of symptoms is not a helpful distinguishing factor, as SS-related dry eye patients experience a wide range of symptoms ranging from asymptomatic dry eye to severe dysfunction and decreased quality of life. Furthermore, there is limited evidence regarding specific ocular signs that in isolation can reliably distinguish SS-related from non-SS-related dry eye for the purpose of identifying SS patients. Thus historically, ocular symptoms and signs in isolation have been poorly predictive of extraocular objective signs required for the diagnosis of SS patients, in particular positive serology and a positive LSG biopsy. However, although ocular signs in isolation may not be useful for diagnosing SS (in the absence of a systemic evaluation), ocular signs may be useful for screening dry eye patients and deciding who should undergo a comprehensive evaluation for SS.
Therefore, the goal of the present study is to explore the association of individual ocular surface diagnostic tests (Schirmer I test, tear breakup time [TBUT], ocular surface staining of the cornea and conjunctiva) with extraocular objective diagnostic tests for SS, thus gaining insight about their potential role in the clinical evaluation algorithm that may be used by ophthalmologists in screening dry eye patients for possible SS. The comprehensive data collected as part of the SICCA study offered a unique opportunity to explore this objective.
Study Design and Population
Enrollment in the SICCA cohort study occurred between 2004 and 2012 in 9 international academic sites in Argentina, China, Denmark, Japan, India, the United Kingdom, and the United States. Institutional Review Board approval of the study protocol was obtained from all centers before the start of the study, and informed consent was obtained from all subjects. The objectives of the SICCA registry, funded primarily by the National Institute of Dental and Craniofacial Research, were to (1) develop new classification criteria for SS, and (2) establish a data and biospecimen repository that would be accessible by investigators worldwide for future studies on the pathogenesis, phenotypic features, and genotypic features of the disease. The data-driven consensus methodology used in the development of classification criteria, and the role of a panel of expert clinicians representing the 3 specialties involved in the diagnosis and management of SS, have been previously described. Expert panel members in the SICCA group agreed that the classification criteria should pertain to a target population of patients who may have signs and symptoms suggestive of SS, and be referred to specialists involved in the diagnosis and management of SS, namely rheumatologists, ophthalmologists, or oral medicine specialists. It was agreed that no diagnostic criteria or labels would be used for enrollment and that all participants in the cohort would undergo the same set of standardized tests and evaluations, including eye examination, labial salivary gland biopsy, and serologic testing (anti-SS A or anti-SS B antibodies or RF positivity in combination with elevated ANA). Thus, patients reporting dry eye symptoms or those who lacked dry eye symptoms but had either extraocular symptoms or signs that may be suggestive of SS were included in the study.
Specifically, to be eligible for the SICCA registry, participants had to be 21 years of age and were required to have 1 or more of the following: (1) symptoms of dry eyes or dry mouth; (2) bilateral parotid enlargement; (3) recent increase in dental caries; (4) a previous suspicion or diagnosis of SS; (5) elevated serology of ANA, positive rheumatoid factor (RF), anti-SS A antibodies, or anti-SS B antibodies; or (6) diagnoses of rheumatoid arthritis or systemic lupus erythematosus. Eligibility criteria were intended to target individuals with signs or symptoms of SS, not the general population and not patients exclusively reporting dry eye symptoms. These represent patients who may have been referred to an ophthalmologist by a rheumatologist or oral medicine specialist in the absence of dry eye symptoms. Exclusion criteria included known diagnoses of the following: hepatitis C, HIV infection, sarcoidosis, amyloidosis, active tuberculosis, graft-vs-host disease, autoimmune connective tissue diseases other than rheumatoid arthritis or systemic lupus erythematosus, or past head and neck radiation treatment.
Further exclusion criteria specific to the eye included current treatment with daily eye drops for glaucoma, corneal surgery in the last 5 years to correct vision, cosmetic eyelid surgery in the last 5 years, or physical or mental condition interfering with successful participation in the study. Contact lens wearers were asked to discontinue use 7 days prior to SICCA examination. We did not exclude participants taking prescription drugs that may affect salivary or lacrimal secretion, but we recorded their use and asked that they discontinue use 1 day prior to the SICCA examination.
Variables and Measures
SICCA registry ocular examination
The sequence and details of the SICCA eye examination protocol have previously been described by the SICCA group, and are only briefly described here. Because ocular surface staining with the vital dyes fluorescein and lissamine green may disrupt tear film stability, Schirmer I test (without anesthesia) was performed first. Next, TBUT, grading of corneal staining with fluorescein (0.5% drops), and grading of conjunctival staining with lissamine green (1% drops) were performed, in that order. Ocular surface staining assessments were performed within a specified time frame before the dye had sufficient time to diffuse and the intensity of the staining could be compromised.
The outcome variables, positive serology and positive LSG biopsy, were defined as follows: (1) positive serology as determined by the presence of SSA or SSB antibodies or RF positivity and ANA titer ≥1:320; (2) LSG biopsy with a diagnosis of FLS and a focus score of ≥1 focus/4 mm 2 . These extraocular outcomes are the other objective tests typically used for the diagnosis of SS, in addition to the ocular surface staining. Thus, they are studied here because they represent the basis of SS classification criteria that was recently endorsed by the ACR.
Summary statistics (proportions for categorical variables; means with 95% confidence intervals [CI] for continuous variables) were used to describe the SICCA participant characteristics with respect to the various objective tests measured (ocular, oral, serologic).
We used logistic regression models to quantify the marginal association between ocular surface diagnostic test results and each of our 2 outcomes (positive LSG biopsy and positive serology). Variables for the ocular test results were defined as follows: (1) binary indicator of an unanesthetized Schirmer I test score ≤5 mm; (2) binary indicator of a TBUT score <10 seconds; (3) conjunctival component of the OSS (graded 0–6 for the conjunctival portion of the grading system) (4); corneal component of the OSS (graded 0–6 for the corneal portion of the grading system); and (5) binary indicator of an OSS score ≥3. P values of less than .05 were deemed statistically significant for regression results. To investigate the independent contribution of the ocular measures in predicting the 2 outcomes, we fitted 2 additional logistic models including the first 4 ocular variables defined above, as well as participant age and race.
All statistical analyses were performed using Stata 10.0 (StataCorp. 2007. Stata Statistical Software: Release 10; StataCorp LP, College Station, Texas, USA) and R (v. 3.0 for MacIntosh; R Foundation for Statistical Computing, Vienna, Austria). Participants with missing values were excluded from the analysis. Missing data occurred as follows: Schirmer score 5.4%, abnormal LSG focus scores 4.8%, and all other variables had smaller fractions of missing data.
Data from a total of 3514 participants were available from the SICCA registry ( Table 1 ). The proportion of participants with an abnormal Schirmer score (defined as ≤5 mm/5 min) was 32%. The majority of participants (85%) had an abnormal TBUT (defined as <10 seconds). The mean conjunctival OSS score was 3 points (95% CI = 2.92–3.06) and the mean corneal OSS score was 2.2 (95% CI = 2.10–2.22). The mean total OSS score was 5.2 (95% CI = 5.03–5.27). The cohort also had the following features: 39.1% had a focus score greater than or equal to 1, 38.3% had a positive SSA or SSB, and 40.9% had positive RF and ANA titer ≥1:320.
|Diagnostic Tests||N (%)|
|Ocular eye tests|
|Schirmer I test|
|Schirmer I test ≤5 mm||1026 (31.7)|
|Schirmer I test >5 mm||2213 (67.7)|
|Tear breakup time|
|<10 seconds||2868 (84.5)|
|≥10 seconds||528 (15.5)|
|Ocular staining score (mean) b|
|Conjunctival score||2.99 (2.92–3.06)|
|Corneal score||2.16 (2.10–2.22)|
|Total OSS score||5.15 (5.03–5.27)|
|Salivary gland biopsy|
|Focus score ≥1||1305 (39.1)|
|Focus score <1||2032 (60.9)|
|SSA or SSB antibodies|
|Not present||2086 (61.7)|
|RF and ANA titer ≥1:320|
|Not present||2000 (59.1)|
Bivariate Analyses Exploring the Association Between Eye-Related Phenotypic Features and Positive Serology and Biopsy
In the bivariate analysis of the independent predictors ( Table 2 ), increased odds of positive serology was associated with abnormal Schirmer test (OR = 2.37, 95% CI = 2.04–2.75, P < .0001) and abnormal TBUT (OR = 2.48, 95% CI = 2.0–3.07, P < .0001). For ocular staining scores, increased odds of positive serology was associated with conjunctival OSS scores (OR = 1.55, 95% CI = 1.49–1.6, P < .0001), corneal OSS scores (OR = 1.43, 95% CI = 1.37–1.49, P < .0001), and an abnormal total OSS score (OR = 1.28, 95% CI = 1.26–1.31, P < .0001).
|Diagnostic Tests||Unadjusted Odds Ratio: Positive Serology (95% CI)||P Value||Unadjusted Odds Ratio: Positive LSG Biopsy (95% CI)||P Value|
|Ocular eye tests|
|Schirmer I test ≤5 mm/min b||2.37 (2.04–2.75)||<.001||2.44 (2.1–2.85)||<.001|
|TBUT <10 seconds b||2.48 (2–3.07)||<.001||2.17 (1.75–2.68)||<.001|
|Ocular staining score|
|Conjunctival OSS score b||1.55 (1.49–1.6)||<.001||1.57 (1.51–1.63)||<.001|
|Corneal OSS score b||1.43 (1.27–1.49)||<.001||1.52 (1.45–1.58)||<.001|
|Abnormal OSS score b||1.28 (1.26–1.31)||<.001||1.31 (1.28–1.34)||<.001|
Positive labial salivary gland biopsy
Similarly, increased odds for having a positive LSG biopsy was associated with abnormal Schirmer score (OR = 2.44, 95% CI = 2.1–2.85, P < .0001) and abnormal TBUT (OR = 2.17, 95% CI = 1.75–2.68, P < .0001). Increased odds of positive LSG biopsy was further associated with conjunctival OSS scores (OR = 1.57, 95% CI: 1.51–1.63, P < .0001), corneal OSS scores (OR = 1.52, 95% CI: 1.45–1.58, P < .0001), and an abnormal OSS score (OR = 1.31, 95% CI = 1.28–1.34, P < .0001).
We fit separate models to explore dry-eye test results as potential explanatory variables of (1) a positive LSG biopsy or (2) positive anti-SSA/B serology. We included 4 independent variables in our models, as follows: abnormal TBUT, abnormal Schirmer test, corneal staining score, and conjunctival staining score. Unadjusted multivariate model results are presented in the Supplemental Table (Supplemental Material available at AJO.com ).
We then fit separate models, adjusting for age and race ( Table 3 ). The odds of a positive focus score on LSG biopsy were significantly higher among those with an abnormal Schirmer test (adjusted OR = 1.26; 95% CI 1.05–1.51, P = .014). In addition, the odds of a positive focus score on LSG biopsy were also significantly higher among those with positive conjunctival staining or corneal staining. Specifically, the adjusted odds ratio for having a positive focus score on LSG biopsy for each additional point of the conjunctival staining score was 1.46 (95% CI 1.39–1.53, P < .001) and for 1 unit of corneal staining score was 1.11 (1.05–1.18, P < .001). In contrast, the odds of a positive focus score on LSG biopsy were significantly lower for those with an abnormal TBUT (adjusted OR 0.76; 95% CI 0.58–0.99; P = .043).